Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Posaconazole Plus PD-1 Inhibitors and Chemotherapy as Neoadjuvant Therapy for TNBC
NCT06802757Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Apr 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of posaconazole in triple-negative breast cancer (TNBC) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: Pathological Complete Response at 24 weeks. Started Apr 2025; status: recruiting.
02
Drugs
posaconazole
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06802757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06802757.